CureVac Announces Late-Breaking Poster Presentation at American Association of Cancer Research (AACR) Annual Meeting 2019
TÜBINGEN, Germany / BOSTON, MA, March 21, 2019 – CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced it will present interim data from its Phase I dose-escalation clinical trial with the RNA-based cancer therapy, CV8102, in patients with advanced solid tumors. These new data have been selected for a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting (AACR) 2019, March 29-April 3, 2019 in Atlanta.
Poster Presentation Details
Title: Intratumoral RNA-based TLR-7/-8 and RIG-I agonist CV8102 alone and in combination with anti-PD-1 in a Phase I dose-escalation and expansion trial in patients with advanced solid tumors
Session Category: Clinical Research / Endocrinology
Session Title: Late-Breaking Research: Clinical Research 1 / Endocrinology
Session Date and Time: Sunday Mar 31, 2019 1:00 PM - 5:00 PM EDT
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 41
Poster Board Number: 13
Permanent Abstract Number: LB-021
About CV8102 and the Phase I Clinical Trial
CV8102, a TLR7/8/RIG-1 agonist based on noncoding single stranded RNA, is designed to modulate the tumor microenvironment after intratumoral injection and to induce immune responses to control injected as well as non-injected distant lesions.
The CV8102 phase I, open-label, dose escalation and expansion study is enrolling patients with advanced melanoma, cutaneous squamous cell carcinoma, squamous cell carcinoma of head and neck, or adenoidcystic carcinoma and superficially injectable tumor lesions.
The trial is currently enrolling patients at multiple clinical sites in Germany. The trial tests escalating doses of single agent CV8102 and CV8102 in combination with licensed anti-PD-1 antibodies.
The primary objective of the study is to assess safety and tolerability. Secondary objectives are to assess preliminary clinical activity and changes in various immune parameters in blood and tumor tissue.
About CureVac AG
CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 19 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines, antibodies and the treatment of rare diseases.
To date, CureVac has received approximately $420 million (€400 million) in equity investments including significant investments from SAP founder Dietmar Hopp’s Dievini and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, Arcturus Therapeutics, Acuitas, and the Bill & Melinda Gates Foundation.
For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.
Jenn Gordon, Media Relations
Global Health PR, New York, United States
T: +1 202-587-2580
Matthew Beck, Vice President Investor Relations
CureVac AG, Boston, MA, United States
T: +1 917-415-1750